Feasibility of clinical evaluation of individuals with increased risk for HPV-associated oropharynx cancer.
Head Neck
; 45(1): 95-102, 2023 Jan.
Article
en En
| MEDLINE
| ID: mdl-36200696
ABSTRACT
BACKGROUND:
Human papillomavirus-associated oropharynx squamous cell carcinoma (HPV-OPSCC) has no known pre-malignant lesion. While vaccination offers future primary prevention, there is current interest in secondary prevention. The feasibility of clinical evaluation of individuals at increased risk for HPV-OPSCC is unclear.METHODS:
Individuals with risk factors for HPV-OPSCC were enrolled in a prospective study (MOUTH). Participants positive for biomarkers associated with HPV-OPSCC were eligible for a clinical evaluation which comprised a head and neck examination and imaging with ultrasound and/or magnetic resonance imaging (MRI). This study was designed to evaluate feasibility of clinical evaluation in a screening study.RESULTS:
Three hundred and eighty-four participants were eligible for clinical evaluation. Of the 384, 204 (53%) completed a head and neck examination or imaging. Of these, 66 (32%) completed MRI (n = 51) and/or ultrasound (n = 64) studies.CONCLUSIONS:
Clinical evaluations, including head and neck examination and imaging, are feasible in the context of a screening study for HPV-OPSCC.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Carcinoma de Células Escamosas
/
Neoplasias Orofaríngeas
/
Infecciones por Papillomavirus
/
Neoplasias de Cabeza y Cuello
Tipo de estudio:
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Año:
2023
Tipo del documento:
Article